Developmental Therapeutics Recent Publications
2024
- Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).Garralda E, Oh DY, Italiano A, Bedard PL, Delord JP, Calvo E, LoRusso P, Wainberg Z, Cervantes A, Rodriguez-Vida A, Shemesh CS, Sane R, Mendus D, Ding H, Hendricks R, Meng R, Cho BC, Kim TW, Wu B. J Clin Pharmacol. 2024 May; 2024 Jan 17. PMID: 38105505.
- Clinical predictive value of renalase in post-ERCP pancreatitis.Muniraj T, Desir G, Gorelick FS, Guo X, Ciarleglio MM, Deng Y, Jamidar PA, Farrell J, Aslanian HR, Laine L. Gastrointest Endosc. 2024 May; 2023 Dec 14. PMID: 38103747.
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update Clinical Insights.Rose MG, Kennedy EB, Abou-Alfa GK, Finn RS, Gade T, Kelley RK, Taddei T, Gordan JD. JCO Oncol Pract. 2024 Apr 25; 2024 Apr 25. PMID: 38662970.
- Hematocrit control and thrombotic risk in patients with polycythemia vera treated with ruxolitinib in clinical practice.Chojecki A, Boselli D, Dortilus A, Hamadeh I, Begley S, Chen T, Bose R, Podoltsev N, Zeidan AM, Balmaceda NB, Yacoub A, Ai J, Knight TG, Ragon BK, Shah NA, Sanikommu SR, Symanowski J, Mesa R, Grunwald MR. Ann Hematol. 2024 Apr 25; 2024 Apr 25. PMID: 38662203.
- Challenges in management of older patients with chronic myeloid leukemia.Stempel JM, Shallis RM, Wong R, Podoltsev NA. Leuk Lymphoma. 2024 Apr 23; 2024 Apr 23. PMID: 38652861.
- Practical utilization of nonlinear spatial encoding: Fast field mapping and FRONSAC-wave.Zhang HZ, Constable RT, Galiana G. Magn Reson Med. 2024 Apr 23; 2024 Apr 23. PMID: 38651264.
- Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix.Bellone S, Jeong K, Halle MK, Krakstad C, McNamara B, Greenman M, Mutlu L, Demirkiran C, Hartwich TMP, Yang-Hartwich Y, Zipponi M, Buza N, Hui P, Raspagliesi F, Lopez S, Paolini B, Milione M, Perrone E, Scambia G, Altwerger G, Ravaggi A, Bignotti E, Huang GS, Andikyan V, Clark M, Ratner E, Azodi M, Schwartz PE, Quick CM, Angioli R, Terranova C, Zaidi S, Nandi S, Alexandrov LB, Siegel ER, Choi J, Schlessinger J, Santin AD. Proc Natl Acad Sci U S A. 2024 Apr 23; 2024 Apr 16. PMID: 38625939.
- Proof-of-concept studies with a computationally designed M(pro) inhibitor as a synergistic combination regimen alternative to Paxlovid.Papini C, Ullah I, Ranjan AP, Zhang S, Wu Q, Spasov KA, Zhang C, Mothes W, Crawford JM, Lindenbach BD, Uchil PD, Kumar P, Jorgensen WL, Anderson KS. Proc Natl Acad Sci U S A. 2024 Apr 23; 2024 Apr 15. PMID: 38621119.
- Constrained alternating minimization for parameter mapping (CAMP).Elsaid MHN, Dispenza LN, Hu C, Peters CD, Constable RT, Tagare DH, Galiana G. Magn Reson Imaging. 2024 Apr 22; 2024 Apr 22. PMID: 38657714.
- Cost-effectiveness of adding quizartinib to induction chemotherapy for patients with FLT3-mutant acute myeloid leukemia.Bewersdorf JP, Patel KK, Shallis RM, Podoltsev NA, Kewan T, Stempel J, Mendez L, Stahl M, Stein EM, Huntington SF, Goshua G, Zeidan AM. Leuk Lymphoma. 2024 Apr 22; 2024 Apr 22. PMID: 38648559.
- Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.Locke FL, Siddiqi T, Jacobson CA, Ghobadi A, Ahmed S, Miklos DB, Perales MA, Munoz J, Fingrut WB, Pennisi M, Gauthier J, Shadman M, Gowda L, Mirza AS, Abid MB, Hong S, Majhail NS, Kharfan-Dabaja MA, Khurana A, Badar T, Lin Y, Bennani NN, Herr MM, Hu ZH, Wang H, Baer A, Baro E, Miao H, Spooner C, Xu H, Pasquini MC. Blood. 2024 Apr 18; 2024 Apr 18. PMID: 38635762.
- Vascular mimicry as a facilitator of melanoma brain metastasis.Provance OK, Oria VO, Tran TT, Caulfield JI, Zito CR, Aguirre-Ducler A, Schalper KA, Kluger HM, Jilaveanu LB. Cell Mol Life Sci. 2024 Apr 18; 2024 Apr 18. PMID: 38635031.
- Treatment of Myelodysplastic Syndromes for Older Patients: Current State of Science, Challenges, and Opportunities.Kewan T, Stahl M, Bewersdorf JP, Zeidan AM. Curr Hematol Malig Rep. 2024 Apr 18; 2024 Apr 18. PMID: 38632155.
- ASCL1 Drives Tolerance to Osimertinib in EGFR Mutant Lung Cancer in Permissive Cellular Contexts.Hu B, Wiesehöfer M, de Miguel FJ, Liu Z, Chan LH, Choi J, Melnick MA, Arnal Estape A, Walther Z, Zhao D, Lopez-Giraldez F, Wurtz A, Cai G, Fan R, Gettinger S, Xiao A, Yan Q, Homer R, Nguyen DX, Politi K. Cancer Res. 2024 Apr 15. PMID: 38359163.
- Multi-omics Analysis Reveals Immune Features Associated with Immunotherapy Benefit in Patients with Squamous Cell Lung Cancer from Phase III Lung-MAP S1400I Trial.Parra ER, Zhang J, Duose DY, Gonzalez-Kozlova E, Redman MW, Chen H, Manyam GC, Kumar G, Zhang J, Song X, Lazcano R, Marques-Piubelli ML, Laberiano-Fernandez C, Rojas F, Zhang B, Taing L, Jhaveri A, Geisberg J, Altreuter J, Michor F, Provencher J, Yu J, Cerami E, Moravec R, Kannan K, Luthra R, Alatrash G, Huang HH, Xie H, Patel M, Nie K, Harris J, Argueta K, Lindsay J, Biswas R, Van Nostrand S, Kim-Schulze S, Gray JE, Herbst RS, Wistuba II, Gettinger S, Kelly K, Bazhenova L, Gnjatic S, Lee JJ, Zhang J, Haymaker C. Clin Cancer Res. 2024 Apr 15. PMID: 38277235.
- Identifying Opportunities to Deliver High-Quality Cancer Care Across a Health System: A Clinical Responsibility.Shah HP, Cohen O, Bourdillon AT, Burtness BA, Boffa DJ, Young M, Judson BL, Mehra S. Otolaryngol Head Neck Surg. 2024 Apr 12; 2024 Apr 12. PMID: 38606669.
- A process to reanalyze clinical DNA sequencing data for biomarker matching in the Lung-MAP Master Protocol.Neal JW, Minichiello K, Brennick R, Huang RSP, Hiemenz MC, Amler C, Patel J, Herbst R, Reckamp KL, Borghaei H, Highleyman L, Redman MW, Pasquina LW, Kozono DE. Oncologist. 2024 Apr 10; 2024 Apr 10. PMID: 38597608.
- pHLIP targeted intracellular delivery of calicheamicin.DuPont M, Klumpp C, Iraca M, Allababidi D, Visca H, Engelman DM, Andreev OA, Moshnikova A, Reshetnyak YK. Int J Pharm. 2024 Apr 10; 2024 Feb 28. PMID: 38428548.
- A Bayesian platform trial design with hybrid control based on multisource exchangeability modelling.Wei W, Blaha O, Esserman D, Zelterman D, Kane M, Liu R, Lin J. Stat Med. 2024 Apr 9; 2024 Apr 9. PMID: 38594809.
- Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147).Sheth SS, Oh JE, Bellone S, Siegel ER, Greenman M, Mutlu L, McNamara B, Pathy S, Clark M, Azodi M, Altwerger G, Andikyan V, Huang G, Ratner E, Kim DJ, Iwasaki A, Levi AW, Buza N, Hui P, Flaherty S, Schwartz PE, Santin AD. Clin Cancer Res. 2024 Apr 9; 2024 Apr 9. PMID: 38592381.
- Long-term exposure to ambient fine particulate matter and risk of liver cancer in the NIH-AARP Diet and Health Study.Ma X, Fisher JA, McGlynn KA, Liao LM, Vasiliou V, Sun N, Kaufman JD, Silverman DT, Jones RR. Environ Int. 2024 Apr 5; 2024 Apr 5. PMID: 38636274.
- Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors.Kahn AM, Perry CJ, Etts K, Kluger H, Sznol M. Oncologist. 2024 Apr 4. PMID: 37971411.
- Validation of a Rule-Based ICD-10-CM Algorithm to Detect Fall Injuries in Medicare Data.Ganz DA, Esserman D, Latham NK, Kane M, Min LC, Gill TM, Reuben DB, Peduzzi P, Greene EJ. J Gerontol A Biol Sci Med Sci. 2024 Apr 3; 2024 Apr 3. PMID: 38566617.
- NCS-1 protein regulates TRPA1 channel through the PI3K pathway in breast cancer and neuronal cells.Sánchez JC, Alemán A, Henao JF, Olaya JC, Ehrlich BE. J Physiol Biochem. 2024 Apr 2; 2024 Apr 2. PMID: 38564162.
- Lifileucel, an Autologous Tumor-infiltrating Lymphocyte Monotherapy, in Patients with Advanced Non-small Cell Lung Cancer Resistant to Immune Checkpoint Inhibitors.Schoenfeld AJ, Lee SM, Doger de Speville B, Gettinger SN, Hafliger S, Sukari A, Papa S, Rodriguez-Moreno JF, Graf Finckenstein F, Fiaz R, Catlett M, Chen G, Qi R, Masteller EL, Gontcharova V, He K. Cancer Discov. 2024 Apr 2; 2024 Apr 2. PMID: 38563600.
- Development of a Small Molecule Downmodulator for the Transcription Factor Brachyury.Chase DH, Bebenek AM, Nie P, Jaime-Figueroa S, Butrin A, Castro DA, Hines J, Linhares BM, Crews CM. Angew Chem Int Ed Engl. 2024 Apr 2; 2024 Feb 28. PMID: 38348945.
- Melanocortin-1 Receptor Expression as a Marker of Progression in Melanoma.Su DG, Djureinovic D, Schoenfeld D, Marquez-Nostra B, Olino K, Jilaveanu L, Kluger H. JCO Precis Oncol. 2024 Apr. PMID: 38662983.
- The Pancreatic Cancer Early Detection (PRECEDE) Study is a Global Effort to Drive Early Detection: Baseline Imaging Findings in High-Risk Individuals.Zogopoulos G, Haimi I, Sanoba SA, Everett JN, Wang Y, Katona BW, Farrell JJ, Grossberg AJ, Paiella S, Klute KA, Bi Y, Wallace MB, Kwon RS, Stoffel EM, Wadlow RC, Sussman DA, Merchant NB, Permuth JB, Golan T, Raitses-Gurevich M, Lowy AM, Liau J, Jeter JM, Lindberg JM, Chung DC, Earl J, Brentnall TA, Schrader KA, Kaul V, Huang C, Chandarana H, Smerdon C, Graff JJ, Kastrinos F, Kupfer SS, Lucas AL, Sears RC, Brand RE, Parmigiani G, Simeone DM. J Natl Compr Canc Netw. 2024 Apr. PMID: 38626807.
- VEGF-C prophylaxis favors lymphatic drainage and modulates neuroinflammation in a stroke model.Boisserand LSB, Geraldo LH, Bouchart J, El Kamouh MR, Lee S, Sanganahalli BG, Spajer M, Zhang S, Lee S, Parent M, Xue Y, Skarica M, Yin X, Guegan J, Boyé K, Saceanu Leser F, Jacob L, Poulet M, Li M, Liu X, Velazquez SE, Singhabahu R, Robinson ME, Askenase MH, Osherov A, Sestan N, Zhou J, Alitalo K, Song E, Eichmann A, Sansing LH, Benveniste H, Hyder F, Thomas JL. J Exp Med. 2024 Apr 1; 2024 Mar 5. PMID: 38442272.
- Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer.Roque DM, Siegel ER, Buza N, Bellone S, Silasi DA, Huang GS, Andikyan V, Clark M, Azodi M, Schwartz PE, Rao GG, Reader JC, Hui P, Tymon-Rosario JR, Harold J, Mauricio D, Zeybek B, Menderes G, Altwerger G, Ratner E, Santin AD. Br J Cancer. 2024 Apr. PMID: 38438590.
- Compartmentalized ocular lymphatic system mediates eye-brain immunity.Yin X, Zhang S, Lee JH, Dong H, Mourgkos G, Terwilliger G, Kraus A, Geraldo LH, Poulet M, Fischer S, Zhou T, Mohammed FS, Zhou J, Wang Y, Malloy S, Rohner N, Sharma L, Salinas I, Eichmann A, Thomas JL, Saltzman WM, Huttner A, Zeiss C, Ring A, Iwasaki A, Song E. Nature. 2024 Apr; 2024 Feb 28. PMID: 38418880.
- Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.Shimony S, Bewersdorf JP, Shallis RM, Liu Y, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Lindsley RC, Chen EC, Ramos Perez J, Stein A, DeAngelo DJ, Neuberg DS, Stone RM, Ball B, Stahl M. Leukemia. 2024 Apr; 2024 Feb 20. PMID: 38378841.
- The dementia care study (D-CARE): Recruitment strategies and demographic characteristics of participants in a pragmatic randomized trial of dementia care.Yang M, Samper-Ternent R, Volpi E, Green AN, Lichtenstein M, Araujo K, Borek P, Charpentier P, Dziura J, Gill TM, Galloway R, Greene EJ, Lenoir K, Peduzzi P, Meng C, Reese J, Shelton A, Skokos EA, Summapund J, Unger E, Reuben DB, Williamson JD, Stevens AB. Alzheimers Dement. 2024 Apr; 2024 Feb 15. PMID: 38358084.
- CD70 is Consistently Expressed in Primary and Metastatic Clear Cell Renal Cell Carcinoma.Huang RR, Chen Z, Kroeger N, Pantuck A, Said J, Kluger HM, Shuch B, Ye H. Clin Genitourin Cancer. 2024 Apr; 2023 Dec 13. PMID: 38195301.
- Self-Assembled nanoparticles of natural bioactive molecules enhance the delivery and efficacy of paclitaxel in glioblastoma.Li Y, Zhao Q, Zhu X, Zhou L, Song P, Liu B, Tian D, Chen Q, Zhou J, Deng G. CNS Neurosci Ther. 2024 Apr; 2023 Dec 4. PMID: 38044793.
- Implementation of a health system intervention to reduce time from presentation to surgical intervention for pediatric testicular torsion.Heckscher D, Jalfon M, Buck MB, Abello A, Nguyen JV, Casilla-Lennon M, Leapman MS, Hittelman AB, Teitelbaum J, Emerson BL, Kenney PA, Cavallo JA, Lambert S. J Pediatr Urol. 2024 Apr; 2023 Nov 2. PMID: 38030428.
- Effect of a Personalized Tobacco Treatment Intervention on Smoking Abstinence in Individuals Eligible for Lung Cancer Screening.Cartmel B, Fucito LM, Bold KW, Neveu S, Li F, Rojewski AM, Gueorguieva R, O'Malley SS, Herbst RS, Toll BA. J Thorac Oncol. 2024 Apr; 2023 Nov 15. PMID: 37977486.
- Unresolved issues with noninferiority pragmatic trials: Results of a literature survey.Ciarleglio MM, Li J, Peduzzi P. Clin Trials. 2024 Apr; 2023 Nov 5. PMID: 37927102.
- It could happen in your backyard.Strazzabosco M. Hepatology. 2024 Apr 1; 2023 Sep 18. PMID: 37722133.
- Essential data variables for a minimum dataset for head and neck cancer trials and clinical research: HNCIG consensus recommendations and database.Baliga S, Abou-Foul AK, Parente P, Szturz P, Thariat J, Shreenivas A, Nankivell P, Bertolini F, Biau J, Blakaj D, Brennan S, Brunet A, De Oliveira TB, Burtness B, Maseda AC, Chow VL, Chua ML, de Ridder M, Garikipati S, Hanai N, Ho FCH, Huang SH, Kiyota N, Klinghammer K, Kowalski LP, Kwong DL, McDowell LJ, Merlano MC, Nair S, Economopoulou P, Overgaard J, Psyrri A, Tribius S, Waldron J, Yom SS, Mehanna H. Eur J Cancer. 2024 Mar 30; 2024 Mar 30. PMID: 38579517.
- Efficacy and Safety of the MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced Biliary Tract Cancer: A Case Series.Yamamoto N, Tolcher A, Hafez N, Lugowska I, Ramlau R, Macarulla T, Geng J, Li J, Teufel M, Märten A, LoRusso P. Onco Targets Ther. 2024; 2024 Mar 29. PMID: 38567193.
- Pembrolizumab plus concurrent chemoradiotherapy versus placebo plus concurrent chemoradiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck (KEYNOTE-412): a randomised, double-blind, phase 3 trial.Machiels JP, Tao Y, Licitra L, Burtness B, Tahara M, Rischin D, Alves G, Lima IPF, Hughes BGM, Pointreau Y, Aksoy S, Laban S, Greil R, Burian M, Hetnał M, Delord JP, Mesía R, Taberna M, Waldron JN, Simon C, Grégoire V, Harrington KJ, Swaby RF, Zhang Y, Gumuscu B, Bidadi B, Siu LL. Lancet Oncol. 2024 Mar 29; 2024 Mar 29. PMID: 38561010.
- EGFR targeting PhosTACs as a dual inhibitory approach reveals differential downstream signaling.Hu Z, Chen PH, Li W, Krone M, Zheng S, Saarbach J, Velasco IU, Hines J, Liu Y, Crews CM. Sci Adv. 2024 Mar 29; 2024 Mar 27. PMID: 38536914.
- Prominent role of gut dysbiosis in the pathogenesis of cystic fibrosis-related liver disease in mice.Bertolini A, Nguyen M, Zehra SA, Taleb SA, Bauer-Pisani T, Palm N, Strazzabosco M, Fiorotto R. J Hepatol. 2024 Mar 28; 2024 Mar 28. PMID: 38554847.
- An algorithm for standardization of tumor Infiltrating lymphocyte evaluation in head and neck cancers.Xirou V, Moutafi M, Bai Y, Nwe Aung T, Burela S, Liu M, Kimple RJ, Shabbir Ahmed F, Schultz B, Flieder D, Connolly DC, Psyrri A, Burtness B, Rimm DL. Oral Oncol. 2024 Mar 27; 2024 Mar 27. PMID: 38547779.
- Iguratimod, an allosteric inhibitor of macrophage migration inhibitory factor (MIF), prevents mortality and oxidative stress in a murine model of acetaminophen overdose.Bloom J, Pantouris G, He M, Aljabari B, Mishra L, Manjula R, Parkins A, Lolis EJ, Al-Abed Y. Mol Med. 2024 Mar 27; 2024 Mar 27. PMID: 38539088.
- Automated graded prognostic assessment for patients with hepatocellular carcinoma using machine learning.Gross M, Haider SP, Ze'evi T, Huber S, Arora S, Kucukkaya AS, Iseke S, Gebauer B, Fleckenstein F, Dewey M, Jaffe A, Strazzabosco M, Chapiro J, Onofrey JA. Eur Radiol. 2024 Mar 27; 2024 Mar 27. PMID: 38536464.
- Enantioselective Sulfonimidamide Acylation via a Cinchona Alkaloid-Catalyzed Desymmetrization: Scope, Data Science, and Mechanistic Investigation.Haas BC, Lim NK, Jermaks J, Gaster E, Guo MC, Malig TC, Werth J, Zhang H, Toste FD, Gosselin F, Miller SJ, Sigman MS. J Am Chem Soc. 2024 Mar 27; 2024 Mar 13. PMID: 38480482.
- Variations in the genomic profiles and clinical behavior of meningioma by racial and ethnic group.Tabor JK, Dincer A, O'Brien J, Lei H, Vetsa S, Vasandani S, Jalal MI, Yalcin K, Morales-Valero SF, Marianayagam N, Alanya H, Elsamadicy AA, Millares Chavez MA, Aguilera SM, Mishra-Gorur K, McGuone D, Fulbright RK, Jin L, Erson-Omay EZ, Günel M, Moliterno J. J Neurosurg. 2024 Mar 22; 2024 Mar 22. PMID: 38518289.
- Clinical Physiology: The Crucial Role of MRI in Evaluation of Peripheral Artery Disease.Elsaid NMH, Peters DC, Galiana G, Sinusas AJ. Am J Physiol Heart Circ Physiol. 2024 Mar 22; 2024 Mar 22. PMID: 38517227.
- Digital spatial proteomic profiling reveals immune checkpoints as biomarkers in lymphoid aggregates and tumor microenvironment of desmoplastic melanoma.Su DG, Schoenfeld DA, Ibrahim W, Cabrejo R, Djureinovic D, Baumann R, Rimm DL, Khan SA, Halaban R, Kluger HM, Olino K, Galan A, Clune J. J Immunother Cancer. 2024 Mar 21; 2024 Mar 21. PMID: 38519058.
- Impact of (18)F-FDG PET Intensity Normalization on Radiomic Features of Oropharyngeal Squamous Cell Carcinomas and Machine Learning-Generated Biomarkers.Haider SP, Zeevi T, Sharaf K, Gross M, Mahajan A, Kann BH, Judson BL, Prasad ML, Burtness B, Aboian M, Canis M, Reichel CA, Baumeister P, Payabvash S. J Nucl Med. 2024 Mar 21; 2024 Mar 21. PMID: 38514087.
- Clinical activity, pharmacokinetics, and pharmacodynamics of oral hypomethylating agents for myelodysplastic syndromes/neoplasms and acute myeloid leukemia: A multidisciplinary review.Haumschild R, Kennerly-Shah J, Barbarotta L, Zeidan AM. J Oncol Pharm Pract. 2024 Mar 21; 2024 Mar 21. PMID: 38509812.
- Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib - pooled analysis from clinical trials.Montesinos P, Fathi AT, de Botton S, Stein EM, Zeidan AM, Zhu Y, Prebet T, Vigil CE, Bluemmert I, Yu X, DiNardo CD. Blood Adv. 2024 Mar 20; 2024 Mar 20. PMID: 38507688.
- Scaffold-Oriented Asymmetric Catalysis: Conformational Modulation of Transition State Multivalency during a Catalyst-Controlled Assembly of a Pharmaceutically Relevant Atropisomer.Tampellini N, Mercado BQ, Miller SJ. Chemistry. 2024 Mar 20; 2024 Mar 20. PMID: 38507249.
- CML and the WHO: Why?Berman E, Shah NP, Deninger M, Altman JK, Amaya M, Begna K, Bhatia R, Chan O, Collins R, Curtin P, DeAngelo DJ, Drazer M, Maness L, Metheny L, Mohan S, Moore J, Oehler V, Pratz K, Pusic I, Rose M, Shomali W, Smith BD, Styler M, Sweet K, Talpaz M, Tanaka T, Tantravahi S, Tsai S, Vaughn J, Welborn J, Yang D, Mauro M, Cortes J, Radich J, Druker B. J Clin Oncol. 2024 Mar 20; 2023 Dec 12. PMID: 38086008.
- Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guideline Update.Gordan JD, Kennedy EB, Abou-Alfa GK, Beal E, Finn RS, Gade TP, Goff L, Gupta S, Guy J, Hoang HT, Iyer R, Jaiyesimi I, Jhawer M, Karippot A, Kaseb AO, Kelley RK, Kortmansky J, Leaf A, Remak WM, Sohal DPS, Taddei TH, Wilson Woods A, Yarchoan M, Rose MG. J Clin Oncol. 2024 Mar 19; 2024 Mar 19. PMID: 38502889.
- Reply to Pisan et al.: Pathogenicity of inherited TRAF7 mutations in congenital heart disease.Mishra-Gorur K, Barak T, Kaulen LD, Henegariu O, Jin SC, Aguilera SM, Yalbir E, Goles G, Nishimura S, Miyagishima D, Djenoune L, Altinok S, Rai DK, Viviano S, Prendergast A, Zerillo C, Ozcan K, Baran B, Sencar L, Goc N, Yarman Y, Ercan-Encicek AG, Bilguvar K, Lifton RP, Moliterno J, Louvi A, Yuan S, Deniz E, Brueckner M, Gunel M. Proc Natl Acad Sci U S A. 2024 Mar 19; 2024 Mar 11. PMID: 38466853.
- The role of surgery and deescalation for HPV-related oropharyngeal cancer.Contrera KJ, Patel MR, Burtness B, Mehra R, Ferris RL. Cancer. 2024 Mar 18; 2024 Mar 18. PMID: 38497569.
- Ligand-gated ion channels as potential biomarkers for ADT-mediated cognitive decline in prostate cancer patients.Verma S, Singh V, Nagampalli V, Ponsky LE, Li CR, Chao H, Gupta S. Mol Carcinog. 2024 Mar 14; 2024 Mar 14. PMID: 38482990.
- Aiming the magic bullet: targeted delivery of imaging and therapeutic agents to solid tumors by pHLIP peptides.Reshetnyak YK, Andreev OA, Engelman DM. Front Pharmacol. 2024; 2024 Mar 13. PMID: 38545547.
- Correction: pH-Responsive fluorescent graphene quantum dots for fluorescence-guided cancer surgery and diagnosis.Fan Z, Zhou S, Garcia C, Fan L, Zhou J. Nanoscale. 2024 Mar 7; 2024 Mar 7. PMID: 38372010.
- A Single Arm Phase 2 Trial of Trametinib in Patients With Locally Advanced or Metastatic Epithelioid Hemangioendothelioma.Schuetze SM, Ballman KV, Heise R, Ganjoo KN, Davis EJ, George S, Burgess MA, Choy E, Shepard DR, Tinoco G, Hirbe A, Kelly CM, Attia S, Deshpande HA, Schwartz GK, Siontis BL, Riedel RF, von Mehren M, Kozlowski E, Chen HX, Astbury C, Rubin BP. Clin Cancer Res. 2024 Mar 6; 2024 Mar 6. PMID: 38446990.
- Enthalpies and entropies of hydration from Monte Carlo simulations.Jorgensen WL. Phys Chem Chem Phys. 2024 Mar 6; 2024 Mar 6. PMID: 38412420.
- Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and Recruitment.Butt A, Christian J, Kress A, Lu BY, Hurwitz ME, Goldberg SB, Podoltsev NA, Gilkes L, Lee AI. J Cancer Educ. 2024 Mar 2; 2024 Mar 2. PMID: 38430454.
- Consensus and controversy in the management of paediatric and adult patients with ovarian immature teratoma: the Malignant Germ Cell International Consortium perspective.Pashankar F, Murray MJ, Gell J, MacDonald N, Shamash J, Billmire DF, Klosterkemper L, Olson T, Hirsch MS, Lockley M, Stoneham S, Frazier AL. EClinicalMedicine. 2024 Mar; 2024 Feb 6. PMID: 38544795.
- Mesothelioma: Pleural, Version 1.2024.Stevenson J, Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, Desai A, Dilling TJ, Dowell J, Durm GA, Garassino MC, Gettinger S, Grotz TE, Gubens MA, Lackner RP, Lanuti M, Lin J, Loo BW Jr, Lovly CM, Maldonado F, Massarelli E, Morgensztern D, Mullikin TC, Ng T, Otterson GA, Owen D, Patel SP, Patil T, Polanco PM, Riely GJ, Riess J, Shapiro TA, Singh AP, Tam A, Tanvetyanon T, Yanagawa J, Yang SC, Yau E, Gregory K, Hang L. J Natl Compr Canc Netw. 2024 Mar. PMID: 38503043.
- Summary of Research: Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC.Tsuboi M, Herbst RS, John T, Kato T, Majem M, Grohé C, Wang J, Goldman JW, Lu S, de Marinis F, Shepherd FA, Lee KH, Le NT, Dechaphunkul A, Kowalski D, Bonanno L, Dómine M, Poole L, Bolanos A, Rukazenkov Y, Wu YL. Target Oncol. 2024 Mar; 2024 Mar 11. PMID: 38466534.
- Disparities in race, ethnicity, sex, and age inclusion in pancreatic cancer screening studies: A systematic review and meta-analysis.Silva-Santisteban A, Hernandez Woodbine MJ, Noriega MA, Rabinowitz LG, Grimshaw A, Farrell JJ, Chhoda A, Sawhney MS. Gastrointest Endosc. 2024 Mar 1; 2024 Mar 1. PMID: 38432492.
- Targeting cervical cancer with anti-PD-1 antibodies: what is new?Greenman M, McNamara B, Mutlu L, Santin AD. Expert Opin Biol Ther. 2024 Mar; 2024 Feb 27. PMID: 38391293.
- IL-10 constrains sphingolipid metabolism to limit inflammation.York AG, Skadow MH, Oh J, Qu R, Zhou QD, Hsieh WY, Mowel WK, Brewer JR, Kaffe E, Williams KJ, Kluger Y, Smale ST, Crawford JM, Bensinger SJ, Flavell RA. Nature. 2024 Mar; 2024 Feb 21. PMID: 38383790.
- Safety profile of pembrolizumab monotherapy based on an aggregate safety evaluation of 8937 patients.Brahmer JR, Long GV, Hamid O, Garon EB, Herbst RS, Andre T, Armand P, Bajorin D, Bellmunt J, Burtness B, Choueiri TK, Cohen EEW, Diaz LA Jr, Shitara K, Kulkarni G, McDermott D, Shah M, Tabernero J, Vogel A, Zinzani PL, Jafari N, Bird S, Snyder E, Gause C, Bracco OL, Pietanza MC, Gruber T, Ribas A. Eur J Cancer. 2024 Mar; 2024 Jan 11. PMID: 38295556.
- Normal Erythroid Precursors in Diamond-Blackfan Anemia: A Rare Case Highlighting Challenges That Remain.Prior D, Sowa A, Pashankar F. J Pediatr Hematol Oncol. 2024 Mar 1; 2024 Jan 25. PMID: 38277626.
- A new prognostic model in chemotherapy-treated patients with recurrent or metastatic head and neck cancer: An analysis of ECOG-ACRIN E1305.Argiris A, Flamand Y, Savvides P, Johnson JM, Vathiotis I, Levine M, Li S, Forastiere AA, Burtness B. Eur J Cancer. 2024 Mar; 2023 Dec 29. PMID: 38215573.
- Immunotherapy Initiation at the End of Life in Patients With Metastatic Cancer in the US.Kerekes DM, Frey AE, Prsic EH, Tran TT, Clune JE, Sznol M, Kluger HM, Forman HP, Becher RD, Olino KL, Khan SA. JAMA Oncol. 2024 Mar 1. PMID: 38175659.
- Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs).Zeidan AM, Mearns ES, Ng CD, Shah A, Lamarre N, Yellow-Duke A, Alrawashdh N, Yang B, Cheng WH, Bui CN, Svensson A. Clin Lymphoma Myeloma Leuk. 2024 Mar; 2023 Oct 30. PMID: 37996264.
- Educational Review: Clinical Application of Immune Checkpoint Blockade for the Treatment of Melanoma.Su D, Kluger H, Olino K. Ann Surg Oncol. 2024 Mar; 2023 Nov 21. PMID: 37989956.
- K-t PCA accelerated in-plane balanced steady-state free precession phase-contrast (PC-SSFP) for all-in-one diastolic function evaluation.Xiang J, Lamy J, Qiu M, Galiana G, Peters DC. Magn Reson Med. 2024 Mar; 2023 Nov 6. PMID: 37927206.
- Cytologic evaluation of upper urinary tract specimens: An institutional retrospective study using The Paris System for Reporting Urine Cytology second edition with histopathologic follow-up.Khajir G, Sun T, Wang H, Sprenkle PC, Adeniran AJ, Cai G, Levi AW. Cytopathology. 2024 Mar; 2023 Nov 2. PMID: 37916579.
- Circulating Tumor Reactive KIR+CD8+ T cells Suppress Anti-Tumor Immunity in Patients with Melanoma.Hafler D, Lu B, Lucca L, Lewis W, Wang J, Nogeuira C, Heer S, Axisa PP, Buitrago-Pocasangre N, Pham G, Kojima M, Wei W, Aizenbud L, Bacchiocchi A, Zhang L, Walewski J, Chiang V, Olino K, Clune J, Halaban R, Kluger Y, Coyle A, Kisielow J, Obermair FJ, Kluger H. Res Sq. 2024 Feb 28; 2024 Feb 28. PMID: 38464315.
- β-amino acids reduce ternary complex stability and alter the translation elongation mechanism.Cruz-Navarrete FA, Griffin WC, Chan YC, Martin MI, Alejo JL, Natchiar SK, Knudson IJ, Altman RB, Schepartz A, Miller SJ, Blanchard SC. bioRxiv. 2024 Feb 27; 2024 Feb 27. PMID: 38464221.
- An oxidative photocyclization approach to the synthesis of Securiflustra securifrons alkaloids.Alexander BW, Bartfield NM, Gupta V, Mercado BQ, Del Campo M, Herzon SB. Science. 2024 Feb 23; 2024 Feb 22. PMID: 38386756.
- Precision needle-punch tumor enrichment from paraffin blocks improves the detection of clinically actionable genomic alterations and biomarkers.Lin DI, Huang RSP, Ladas I, Keller RB, Patel NR, Lakis S, Decker B, Janovitz T, Mata DA, Ross JS, Vergilio JA, Elvin JA, Herbst RS, Mack PC, Killian JK. Front Oncol. 2024; 2024 Feb 20. PMID: 38444675.
- Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND).Badar T, Nanaa A, Atallah E, Shallis RM, Guilherme SCC, Goldberg AD, Saliba AN, Patel A, Bewersdorf JP, DuVall AS, Bradshaw D, Abaza Y, Murthy GSG, Palmisiano N, Zeidan AM, Kota V, Litzow MR. Blood Cancer J. 2024 Feb 20; 2024 Feb 20. PMID: 38378617.
- Multiplexable and Scalable Aqueous Synthesis Platform for Oleate-Based, Bilayer-Coated Gold Nanoparticles.Backhaus A, Albrecht J, Alzhanova G, Long A, Arnold W, Lee J, Tse HY, Su TT, Cruz-Gomez S, Lee SSS, Menges F, Parent LR, Ratjen L, Burtness B, Fortner JD, Zimmerman JB. Small. 2024 Feb 20; 2024 Feb 20. PMID: 38377304.
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, Kim KB, McKean M, Long GV, Sullivan RJ, Faries M, Tran TT, Cowey CL, Pecora A, Shaheen M, Segar J, Medina T, Atkinson V, Gibney GT, Luke JJ, Thomas S, Buchbinder EI, Healy JA, Huang M, Morrissey M, Feldman I, Sehgal V, Robert-Tissot C, Hou P, Zhu L, Brown M, Aanur P, Meehan RS, Zaks T. Lancet. 2024 Feb 17; 2024 Jan 18. PMID: 38246194.
- Entinostat, nivolumab and ipilimumab for women with advanced HER2-negative breast cancer: a phase Ib trial.Roussos Torres ET, Ho WJ, Danilova L, Tandurella JA, Leatherman J, Rafie C, Wang C, Brufsky A, LoRusso P, Chung V, Yuan Y, Downs M, O'Connor A, Shin SM, Hernandez A, Engle EL, Piekarz R, Streicher H, Talebi Z, Rudek MA, Zhu Q, Anders RA, Cimino-Mathews A, Fertig EJ, Jaffee EM, Stearns V, Connolly RM. Nat Cancer. 2024 Feb 14; 2024 Feb 14. PMID: 38355777.
- The European Union Ban on Microplastics Includes Artificial Turf Crumb Rubber Infill: Other Nations Should Follow Suit.Zuccaro P, Thompson DC, de Boer J, Llompart M, Watterson A, Bilott R, Birnbaum LS, Vasiliou V. Environ Sci Technol. 2024 Feb 13; 2024 Feb 1. PMID: 38301275.
- Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.McNamara B, Demirkiran C, Hartwich TMP, Bellone S, Manavella D, Mutlu L, Greenman M, Zipponi M, Yang-Hartwich Y, Yang K, Ratner E, Schwartz PE, Coma S, Pachter JA, Santin AD. Gynecol Oncol. 2024 Feb 9; 2024 Feb 9. PMID: 38493021.
- Encoding scheme design for gradient-free, nonlinear projection imaging using Bloch-Siegert RF spatial encoding in a low-field, open MRI system.Selvaganesan K, Ha Y, Sun H, Zhang Z, Sun C, Samardzija A, Galiana G, Constable RT. Sci Rep. 2024 Feb 8; 2024 Feb 8. PMID: 38332252.
- Immunotherapy utilization in stage IIIA melanoma: less may be more.Frey AE, Kerekes DM, Khan SA, Tran TT, Kluger HM, Clune JE, Ariyan S, Sznol M, Ishizuka JJ, Olino KL. Front Oncol. 2024; 2024 Feb 6. PMID: 38380358.
- Community-Level Factors Associated with Hepatocellular Carcinoma Incidence and Mortality: An Observational Registry Study.Mezzacappa C, Rossi R, Jaffe A, Taddei TH, Strazzabosco M. Cancer Epidemiol Biomarkers Prev. 2024 Feb 6. PMID: 38059831.
- A comprehensive trial on PFAS remediation: hemp phytoextraction and PFAS degradation in harvested plants.Nason SL, Thomas S, Stanley C, Silliboy R, Blumenthal M, Zhang W, Liang Y, Jones JP, Zuverza-Mena N, White JC, Haynes CL, Vasiliou V, Timko MP, Berger BW. Env Sci Adv. 2024 Feb 5; 2024 Jan 5. PMID: 38322792.
- Clinical Outcomes Among Immunotherapy-Treated Patients With Primary Cardiac Soft Tissue Sarcomas: A Multicenter Retrospective Study.Nassar AH, El-Am E, Denu R, Abou Alaiwi S, El Zarif T, Macaron W, Abdel-Wahab N, Desai A, Smith C, Parikh K, Abbasi M, Bou Farhat E, Williams JM, Collins JD, Al-Hader A, McKay RR, Malvar C, Sabra M, Zhong C, El Alam R, Chehab O, Lima J, Phan M, Dalla Pria HF, Trevino A, Neilan TG, Kwan JM, Ravi V, Deshpande H, Demetri G, Choueiri TK, Naqash AR. JACC CardioOncol. 2024 Feb; 2024 Jan 16. PMID: 38510282.
- Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country.Awidi A, Alzu'bi M, Odeh N, Alrawabdeh J, Al Zyoud M, Hamadneh Y, Bawa'neh H, Magableh A, Alshorman A, Al-Fararjeh F, Aladily T, Zeidan AM. JCO Glob Oncol. 2024 Feb. PMID: 38422464.
- Circulating Tumor DNA Dynamics Fail to Predict Efficacy of Poly(ADP-ribose) Polymerase/VEGFR Inhibition in Patients With Heavily Pretreated Advanced Solid Tumors.Hu Y, Narayan A, Xu Y, Wolfe J, Vu D, Trinh T, Kantak C, Ivy SP, Eder JP, Deng Y, LoRusso P, Kim JW, Patel AA. JCO Precis Oncol. 2024 Feb. PMID: 38412387.
- The importance of considering competing risks in recurrence analysis of intracranial meningioma.Mirian C, Jensen LR, Juratli TA, Maier AD, Torp SH, Shih HA, Morshed RA, Young JS, Magill ST, Bertero L, Stummer W, Spille DC, Brokinkel B, Oya S, Miyawaki S, Saito N, Proescholdt M, Kuroi Y, Gousias K, Simon M, Moliterno J, Prat-Acin R, Goutagny S, Prabhu VC, Tsiang JT, Wach J, Güresir E, Yamamoto J, Kim YZ, Lee JH, Koshy M, Perumal K, Baskaya MK, Cannon DM, Shrieve DC, Suh CO, Chang JH, Kamenova M, Straumann S, Soleman J, Eyüpoglu IY, Catalan T, Lui A, Theodosopoulos PV, McDermott MW, Wang F, Guo F, Góes P, de Paiva Neto MA, Jamshidi A, Komotar R, Ivan M, Luther E, Souhami L, Guiot MC, Csonka T, Endo T, Barrett OC, Jensen R, Gupta T, Patel AJ, Klisch TJ, Kim JW, Maiuri F, Barresi V, Tabernero MD, Skyrman S, Broechner A, Bach MJ, Law I, Scheie D, Kristensen BW, Munch TN, Meling T, Fugleholm K, Blanche P, Mathiesen T. J Neurooncol. 2024 Feb; 2024 Feb 10. PMID: 38336917.
- May we actually help clinicians select the best systemic treatment for patients with intermediate-stage hepatocellular carcinoma?Giannini EG, Strazzabosco M. Liver Int. 2024 Feb. PMID: 38289589.
- Increased von Willebrand and Factor VIII plasma levels in gynecologic patients with Post-Acute-COVID-Sequela (PASC)/Long COVID.Bellone S, Siegel ER, Scheim DE, Santin AD. Gynecol Oncol Rep. 2024 Feb; 2024 Jan 4. PMID: 38273933.
- Racial differences in treatment and survival among older patients with multiple myeloma.Wang R, Neparidze N, Ma X, Colditz GA, Chang SH, Wang SY. Cancer Med. 2024 Feb; 2024 Jan 17. PMID: 38234237.